Rosemary J. Hollick

Rosemary J. Hollick

Auto-generated profile, based on publicly available information

Rosemary J. Hollick

Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2023 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
JKJ.A. Kanis
J.A. Kanis
HJH. Johansson
H. Johansson
EME.V. McCloskey
E.V. McCloskey
Enwu LiuEnwu Liu
Enwu Liu
KÅKRISTINA E ÅKESSON
KRISTINA E ÅKESSON
WLW.D. Leslie
W.D. Leslie

31 May 2022 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
LVL. Vandenput
L. Vandenput
HJH. Johansson
H. Johansson
EME. V. McCloskey
E. V. McCloskey
Enwu LiuEnwu Liu
Enwu Liu
KÅKRISTINA E ÅKESSON
KRISTINA E ÅKESSON
JKJ. A. Kanis
J. A. Kanis

17 January 2024 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
LVLiesbeth Vandenput
Liesbeth Vandenput
HJHelena Johansson
Helena Johansson
EMEugene V. McCloskey
Eugene V. McCloskey
Enwu LiuEnwu Liu
Enwu Liu
Marian SchiniMarian Schini
Marian Schini
JKJohn A. Kanis
John A. Kanis

12 April 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
LRLynn Robertson
Lynn Robertson
CBCorrinda Black
Corrinda Black
NFNick Fluck
Nick Fluck
SGSharon Gordon
Sharon Gordon
RHRosemary Hollick
Rosemary Hollick
AMAngharad Marks
Angharad Marks
Background Individuals on renal replacement therapy (RRT) have increased fracture risk, but risk in less advanced chronic kidney disease (CKD) is unclear. Objective To investigate CKD associations with hip fracture incidence and mortality. Design Record linkage cohort study Grampian Laboratory Outcomes Mortality and Morbidity Study II. Setting Single health region in Scotland. Participants All individuals (≥15 years) with sustained CKD stages 3–5 and those on RRT, and a 20% random sample of those with normal renal function, in the resident population in 2003. Outcome measures Outcomes were (1) incident hip fracture measured with (A) admissions or (B) deaths, with at least 5.5 years follow-up and (2) post-hip fracture mortality. Unadjusted and adjusted, incident rate ratios (IRRs) and mortality rate ratios were calculated using Poisson regression. Results Of 39 630 individuals identified in 2003 (41% males, mean age 63.3 years), 19 537 had CKD stages 3–5, 345 were on RRT and 19 748 had normal estimated glomerular filtration rate (eGFR). Hip fracture incidence, measured by admissions, was increased in CKD stages 3–5 (compared with normal eGFR), both overall (adjusted IRR 1.49 (95% CI 1.24 to 1.79)) and for individual CKD stages 3a, 3b and 4. Hip fracture incidence, measured using deaths, was increased in those with CKD stages 3b and 4. Post-hip fracture mortality was only increased in CKD stage 4. There was only a small number of individuals and events for CKD stage 5, resulting in insufficient statistical power. Conclusion Hip fracture incidence was higher in CKD stages 3–5 compared with normal eGFR. Post-hip fracture mortality was only increased in CKD stage 4. Reducing hip fracture incidence in CKD through regular fall and fracture risk review should reduce overall deaths after hip fracture in the population.

20 March 2020 in Pain
Verified
Journal Article
Closed access
SDStefanie Doebl
Stefanie Doebl
GMGary Macfarlane
Gary Macfarlane
RHRosemary J. Hollick
Rosemary J. Hollick
Fibromyalgia is a common and complex long-term pain condition. Despite advancements in our understanding and treatment of fibromyalgia, patients report patchy health care provision and frustrating journeys through the health care system. To inform how best to deliver care, we undertook 2 narrative reviews examining existing evidence on (1) models of care for fibromyalgia and (2) patients' experiences, preferences, and unmet needs regarding their health care. Seven databases were systematically searched. Quantitative data was narratively synthesised and qualitative data thematically analysed. No evidence-based model of care covering the patient journey through the entire health care system was identified. Limited evidence suggests no clear benefit for ongoing care in secondary care settings. Patients with fibromyalgia report difficult interactions with the health care system that might equally be expressed by those with other long-term conditions, such as inconsistent and poorly coordinated care. However, they also face unique problems; fibromyalgia was often not viewed as a real condition, resulting in difficult encounters with health care staff, in particular not feeling believed or listened to. Significant delays in diagnosis were commonplace. Positive care experiences such as being listened to and shared decision-making made patients feeling better informed, well supported, and more satisfied. There is little evidence to inform how best to organise health care for patients with fibromyalgia and ensure care is delivered in a coordinated and consistent way. These findings provide a strong rationale for developing a new model of care for fibromyalgia.

12 June 2025 in Rheumatology
Verified
Journal Article
Open access
KBKathryn Biddle
Kathryn Biddle
JJJudith Jade
Judith Jade
HWHarold Wilson-Morkeh
Harold Wilson-Morkeh
MAMadura Adikari
Madura Adikari
CYChadwan Al Yaghchi
Chadwan Al Yaghchi
CCCoziana Ciurtin
Coziana Ciurtin
ANCA-associated vasculitis (AAV) is comprised of three specific conditions: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). Since the publication of the last British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) guideline for the management of adults with AAV in 2014, a plethora of randomized controlled trials, additional research and recommendations have provided novel insights into how the management of AAV can be optimized, thus improving patient quality of life. The BSR AAV Working Group (WG) reviewed published guidelines, undertook a systematic literature review and utilized expertise from specialist vasculitis centres across the UK and patient representatives to formulate a list of 26 recommendations with corresponding strength of agreement (SOA) scores. Recommendations were updated from the published 2014 BSR and BHPR guideline. The 26 recommendations encompassed five key domains: 1. Treatment for GPA and MPA; 2. Management of subglottic stenosis and ear, nose and throat (ENT) manifestations of AAV; 3. Management and treatment for EGPA; 4. Service specifications; 5. Patient education and support. These recommendations provide an update on care delivery of AAV based on current evidence and specialist opinion. In addition, we have provided research and audit recommendations to support equitable access to care and improve health outcomes. The lay summary that accompanies this abstract can be found in Supplementary Data S1, available at Rheumatology online.